Trial Profile
An open-label, randomized phase III study of Early switch maintenance vs DElayed second-line Nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 06 Oct 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms EDEN
- 30 Sep 2022 Planned End Date changed from 30 Sep 2022 to 31 Jan 2023.
- 30 Sep 2022 Planned primary completion date changed from 30 Sep 2022 to 31 Jan 2023.
- 14 Sep 2020 Status changed from recruiting to active, no longer recruiting.